The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.
Semaglutide and potentially other GLP-1 receptor agonists slow CKD progression. Credit: sweet_tomato via Shutterstock. The ...
Individual patients may have substantial differences in their eGFRcr and eGFRcys for estimating kidney function, which has prognostic implications.
Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...
4d
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney ...
ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of ...
The deceleration in CKD prevalence growth after 2012, along with the declining incidence trends may reflect the impact of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback